Company: Xcellerex
Based: Marlborough, MA
Amount: $41.84M
Round: Third
Investors: Biotechonomy Ventures, Kleiner Perkins Caufield & Byers, Undisclosed Investor, VantagePoint Venture Partners

Scoop: Xcellerex raised $41.84 million in two separate rounds last year. During the first round in January, the company raised $11 million to finance commercialization of a manufacturing program that uses disposable components to produce multiple products. In another round in October, Xellerex gained $31 million for "development and commercialization of its proprietary FlexFactory manufacturing system and XDR bioreactors for the production of biomolecules, including biotherapeutics and vaccines, and for developing its own internal biomolecule products."

More News:
Xcellerex gains $11M in new venture funds. Report


Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.